Since
1947, 70 years of delivering the value
of beauty
LG
Chem, realizing the customer value with market-leading
products and services in basic components, battery,
information and electronic materials, and bio-industry.
LG Chem also has a long history of over 70 years
in the aesthetics industry. Yeonam, the founder
of LG Group, started a cosmetics retail store
in Busan, Korea, in 1945. He has selected cosmetics
retail as the main business among many others
since “cosmetics will always exist as people
want to be beautiful.” When he saw the cosmetics
retail business succeeded, he founded Lucky Chemical
Engineering in 1947 and launched ‘Lucky Cream’
to seriously start cosmetics manufacturing.
In
the process of upgrading lids, the company started
developing plastic materials and manufactured
the first processed plastic products in 1952,
to improve the quality of their lids.
At
the end of 1983, LG Chem built the first cosmetics
company in Korea and manufactured basic cosmetics
and makeup products with Helena Rubinstein of
America. In 1985, LG independently produced
123 products including 32 kinds of basic cosmetics
and perfumes.
Since
1990, a different type of
beauty developed from 30 years of ingredient
research
LG
Chem has secured a unique R&D
potential which was approved for the
first time in Korea for new drug by
the FDA in USA. It has continued to
grow as a global pharmaceutical company
by expanding pipelines to develop
new chemicals with investment and
R&D competence. LG Chem has studied
hyaluronic acid products since 1990.
It launched solutions used for ophthalmic
surgery in 1995, and a drug for osteoarthritis
in 2005, using hyaluronic acid ingredients.
With
the accumulated knowledge, LG Chem
launched the first Korean hyaluronic
acid filler, YVOIRE®
Classic,in
the Korean aesthetic market. LG
Chem’s own 30 years of accumulated
knowledge from the ingredient research
has naturally been presented in
their outstanding quality and it
has provided a unique competitiveness
of YVOIRE®.
It has become the unrivaled competitiveness
of YVOIRE®
realizing the beauty, the customers
want in an effective and safe way.
Since
2010, the beauty of YVOIRE®delivered
to the world beyond asia
YVOIRE®
the
filler product directly manufactured
by LG Chem from the raw material to
end product, well-regarded in Asian
markets, especially in South Korea
and China since its launch in 2010,
calling for a change in the existing
Asian aesthetics market which previously
considered European products superior.
Achieving unrivaled share in Korean
and Chinese markets in 2017, YVOIRE®
now is exported to more than 40 countries
in Asia, Europe, and South America.
Recognized
for its contribution in the dramatic
increase of experts, YVOIRE®was
selected as the world’s best
product in 2016, certified by the
Minister of Trade, Industry and
Energy of Korea. This means that
YVOIRE®
has been recognized as a competent
product. As noted above, YVOIRE®
provides
a product with high value in beauty
to the customers around the world
that was profoundly built in the
aesthetics industry.
Clovers Malaysia - Enhancing beauty and confidence through high-quality medical aesthetic solutions
LG
Chem, one of South Korea's leading chemical
companies, renowned for its innovation
across various industries, including biotechnology
and cosmetics, LG Chem has built a reputation
for excellence and reliability. LG
Chem rises as the Global Top 5 Chemical
Company since 2022.
30
Years of Expertise in HA
LG
Chem has developed and manufactured
hyaluronic acid (HA) pharmaceutical
products for more than 30 years, its
non-animal origin HA has been marketed
in various medical fields since 1995
with proven safety and efficacy:
1990
Hyaluronic
acid R&D started with Producer
Strain Development.
1995
'Hyal
2000®Inj.' 1st Hyaluronic Acid
Ophthalmic Viscoelastics developed
in Korea.
2005
'Hyruan
Plus®Inj.' 1st 3-Injection Hyaluronic
Acid Viscosupplement for Osteoarthritis
launched in Korea.
2011
YVOIRE®,
1st cross-linked Hyaluronic Acid
Filler developed in Korea.
2013
YVOIRE®Plus, 1st Hyaluronic Acid
Filler with Lidocaine developed
in Korea.
Authorized
Quality of HA Raw Material
LG
Chem is one of the few
company that fully controls
the quality and safety
from HA raw material to
end-product. LG Chem
is high molecular weigh
HA is manufactured according
to Good Manufacturing
Practice (GMP) Rules and
listed in US FDA Drug
Master File (DMF), approved
by the European Directorate
for the Quality of Medicines,
EDQM.
Reliable
HA Dermal Filler
YVOIRE®is CE (Conformité
Européene) approved in
2013 and registered under Medical
Device Authority Malaysia (MDA).
Natural
and Safe
As
the first HA filler
brand in Korea, YVOIRE®has gained global
brand recognition with
more than 11 million
syringes shipped over
44 countries, credits
to its established safety
profile and improved
efficacy.
As
of November 2020 / The
countries shown on the
map may not be accurate.
HICE™Cross-linking
Technology
HICE™
stands
for ‘High Concentration Equalized’,
a cross-linking technology developed
by LG Chem, utilizes specialized
instruments and precision controls
during its HA processing, ensuring
a maximum rate of crosslinking
while preserving the natural HA
structure (low modification degree,
MoD). This meticulous process
also optimizes the dispersion
of the crosslinking agent, delivering
superior product consistency and
effectiveness.
Low
modification degree
of 1.8% to 2.0%
High
cross-linking ratio
Cross-linking ratio
of HA filler products
CrR
: The number of
cross linked BDDE
among the total
BDDE
Diagram by LG
Chem SOURCE: Galderma’s
patent, WO 2014/206701
A1
Having
continued to grow over 7 decades since founded in
1947, LG Chem is literally the company leading the
chemical industry in Korea. The company has strengthened
market dominance starting from the Basic Materials
& Chemicals business to Energy Solution, IT and
Electronic Materials and has expanded its business
into Life Science area, building a future-oriented
business portfolio.
LG
Chem helps the people to lead a healthy life by
strengthening its R&D competence in Life Sciences.
Life Sciences is the company's new growth engine
in the mid to long term goal.
The
company has secured the differentiated R&D
competence and has received the U.S. FDA approval
for its new drugs for the first time in Korea.
Based on our superior biotechnology and R&D
capabilities accumulated since 1980s, we have
been successful in developing a variety of original
products including Korea's first growth hormone
for children, new drugs for diabetes, etc. At
the same time, we have continuously expanded our
competitive edge through cooperation with global
pharmaceutical companies.
HEADQUARTER
CLOVERS
BIOTECHOLOGY SDN BHD
No.12, Lorong Teknologi B,
Nouvelle Industrial Park,
Taman Sains Selangor 1, PJU5,
47810 Petaling Jaya, Selangor, Malaysia.
Portfolio
